基本信息

姓名：王媛

职称：研究员

电子邮箱：yuanwangimu@imu.edu.cn 

教育经历

2012/09-2017/06，南开大学，生物化学与分子生物学，博士

2008/09–2012/07，内蒙古大学，生物科学，学士

工作经历

2017/06-2023/06，南开大学药物化学生物学国家重点实验室，助理研究员

2023/08-至今，内蒙古大学生物医学研究院，研究员

研究方向

肿瘤和感染性疾病的生物技术药物研发及其作用机理研究

代表性论文

代表性论文（#共同一作，*共同通讯）：

1.Shiyu Liu; Fan Li; Qiongqiong Ma; Mingjuan Du; Haoran Wang; Yiping Zhu; Li Deng; Wenrui Gao; Chunlei Wang; Yanqin Liu; Zhuoqian Zhao; Huanzhen Liu; Ruikun Wang; Yujie Tian; Manli Hu; Yajuan Wan; Wenyi Lu; Meng Zhang; Mingfeng Zhao; Youjia Cao; Hongkai Zhang; Wei Wang*; Hui Wang*; Yuan Wang*; OX40L-Armed Oncolytic Virus Boosts T-cell Response and Remodels Tumor Microenvironment for Pancreatic Cancer Treatment. Theranostics, 2023; 13(12):4016-4029.

2.Yuan Wang#; Ruina Jin#; Bingqing Shen; Na Li; He Zhou; Wei Wang; Yingjie Zhao; Mengshi Huang; Pan Fang; Shanshan Wang; Pascaline Mary; Ruikun Wang; Peixiang Ma; Ruonan Li; Yujie Tian; Youjia Cao; Fubin Li; Liang Schweizer; Hongkai Zhang* ; High-throughput functional screening for next-generation cancer immunotherapy using droplet-based microfluidics, Science Advances, 2021, 7(24): eabe3839

3.Fengping Peng#; Yuan Wang#; Jiliang Zhao; Hui Liu; Zhaoyun Liu; Kai Ding; Hongkai Zhang*; Rong Fu* ; Gene therapy with B-cell maturation antigen/CD3 bispecific antibody encoding plasmid DNA for treating multiple myeloma, British Journal of Haematology, 2022

4.Yuan Wang; Fuquan Chen; Man Zhao; Zhe Yang; Jiong Li; Shuqin Zhang; Weiying Zhang; Lihong Ye*; Xiaodong Zhang* ; The long noncoding RNA HULC promotes liver cancer by increasing the expression of the HMGA2 oncogene via sequestration of the microRNA-186, Journal of Biological Chemistry, 2017, 292(37): 15395-15407

5.Yuan Wang; Fuquan Chen; Zhe Yang; Man Zhao; Shuqin Zhang; Yuen Gao; Jinyan Feng; Guang Yang; Weiying Zhang; Lihong Ye*; Xiaodong Zhang* ; The Fragment HMGA2-sh-3p20 from HMGA2 mRNA 3'UTR Promotes the Growth of Hepatoma Cells by Upregulating HMGA2, Scientific Reports, 2017, 7(1):2070-2070

已授权的发明专利

1.张宏恺 王媛， 抗CD40抗体及其用途, 国际专利，WO 2020/207470 A1,  已授权给医药公司。

2.张宏恺 王媛 晋瑞娜，抗OX40抗体及其用途, 国际专利，WO 2021/129874 A1, 已授权给医药公司（该抗体目前已进入临床I期，临床批号NCT05229601）。